Comparative Pharmacology
Head-to-head clinical analysis: EPRONTIA versus EXTENDED PHENYTOIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPRONTIA versus EXTENDED PHENYTOIN SODIUM.
EPRONTIA vs EXTENDED PHENYTOIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by inhibiting presynaptic serotonin reuptake.
Phenytoin stabilizes neuronal membranes by promoting sodium channel inactivation, reducing repetitive firing of action potentials, and decreasing synaptic transmission.
Adults: 200-800 mg twice daily orally, starting at 200 mg twice daily, increasing by 200 mg/day weekly to maintenance.
Oral: 100 mg three times daily; intravenous: 10-20 mg/kg loading dose at a maximum rate of 50 mg/min, then 100 mg every 6-8 hours maintenance.
None Documented
None Documented
Terminal elimination half-life is 20–30 hours in adults with normal renal function; prolonged to 40–60 hours in moderate to severe renal impairment (CrCl <50 mL/min), requiring dose adjustment.
22–32 hours (mean 24 hours) in adults, dose-dependent due to saturable metabolism; may exceed 60 hours at high concentrations.
Renal excretion of unchanged drug accounts for approximately 70% of elimination, with 30% metabolized hepatically; metabolites are also renally excreted. Fecal elimination is minimal (<5%).
Primarily hepatic metabolism (CYP2C9/CYP2C19), with <5% excreted unchanged renally. Fecal excretion accounts for minor elimination.
Category C
Category D/X
Anticonvulsant
Anticonvulsant